Immuneering a Aktie
WKN DE: A3CWDN / ISIN: US45254E1073
25.08.2025 14:48:25
|
Immuneering, Lilly In Clinical Supply Agreement To Evaluate Atebimetinib Plus Olomorasib For NSCLC
(RTTNews) - Immuneering Corporation (IMRX), a clinical-stage oncology company, Monday said it has signed a clinical supply agreement with Eli Lilly and Company (LLY) for Lilly's olomorasib.
Imuneering plans to evaluate its lead drug candidate atebimetinib in combination with olomorasib in a Phase 2 study in patients with non-small cell lung cancer (NSCLC).
In February this year, Immuneering had announced partnership with Regeneron Pharmaceuticals to evaluate atebimetinib in combination with Libtayo in advanced NSCLC.

Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Immuneering Corp Registered Shs -A-mehr Nachrichten
Keine Nachrichten verfügbar. |
Analysen zu Immuneering Corp Registered Shs -A-mehr Analysen
Aktien in diesem Artikel
Immuneering Corp Registered Shs -A- | 9,23 | 7,45% |
|